目的:探讨血液透析中低血压患者采用左卡尼汀治疗临床疗效及对患者血压及微炎症的影响。方法:截选慈溪市人民医院2012年3月-2015年3月60例血液透析中低血压患者,按照随机数字表法分组为对照组(注射生理盐水及高渗葡萄糖等治疗)与观察组(透析完后注射1.0g左卡尼汀)。记录两组患者血液透析前、透析开始后2h及结束后血压情况,统计两组患者治疗前、后微炎症变化,同时统计患者临床疗效及安全性。结果:治疗后,两组患者CRP和IL-6及TNF-α水平较治疗前显著下降,观察组较对照组下降更显著,P<0.05;治疗前,两组患者血压值比较,P>0.05,透析后,两组均出现明显血压下降,但对照组下降更显著,P<0.05。观察组治疗有效率为70.0%明显高于对照组36.7%,P<0.05;治疗期间均未见明显不良反应。结论:应用左卡尼汀治疗血液透析中低血压临床疗效显著且安全。 Objective: To investigate the clinical efficacy of levocarnitine and its effect on blood pressure and micro-inflammation in hemodialysis patients with hypotension. Methods: Cixi People’s Hospital was selected from March 2012 to March 2015, 60 cases of hemodialysis patients with hypotension were randomly divided into control group (injection of normal saline and hypertonic glucose) and observation group ( After dialysis injection 1.0g L-carnitine). The blood pressure of two groups before and after dialysis were recorded. The changes of micro-inflammation before and after treatment were recorded and the clinical efficacy and safety were recorded. Results: After treatment, the levels of CRP, IL-6 and TNF-αwere significantly decreased in both groups compared with the control group before treatment, P <0.05; before treatment, the blood pressure values ​​of the two groups were compared, P> 0.05 After dialysis, both groups showed a significant decrease in blood pressure, but the control group decreased more significantly, P <0.05. The effective rate of observation group was 70.0%, which was significantly higher than that of control group (36.7%, P <0.05). No obvious adverse reactions were observed during the treatment. Conclusion: The clinical efficacy of levocarnitine in the treatment of hypotension in hemodialysis is significant and safe.